Patents by Inventor Douglas P. Gladue

Douglas P. Gladue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210244809
    Abstract: Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate (“ASFV-G”). An exemplary vaccine comprises the ASFV-G?I1771 modified virus, a recombinant ASFV-G modified by deleting a portion of the I177L ORF rendering the I177L gene nonfunctional.
    Type: Application
    Filed: April 6, 2021
    Publication date: August 12, 2021
    Inventors: Douglas P. GLADUE, MANUEL V. BORCA
  • Patent number: 11007263
    Abstract: Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate (“ASFV-G”). An exemplary vaccine comprises the ASFV-G?I1771 modified virus, a recombinant ASFV-G modified by deleting a portion of the I177L ORF rendering the I177L gene nonfunctional.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: May 18, 2021
    Assignee: The United States of America, as represented by The Secretary of Agriculture
    Inventors: Douglas P. Gladue, Manuel V. Borca
  • Publication number: 20210085776
    Abstract: Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate (“ASFV-G”). An exemplary vaccine comprises the ASFV-G?I1771 modified virus, a recombinant ASFV-G modified by deleting a portion of the I177L ORF rendering the I177L gene nonfunctional.
    Type: Application
    Filed: September 24, 2019
    Publication date: March 25, 2021
    Inventors: Douglas P. GLADUE, MANUEL V. BORCA
  • Patent number: 9814771
    Abstract: The role of a specific E2 region containing a putative fusion peptide (FP) sequence was evaluated. FPs critically contribute to the interaction between proteins and the membrane system of the host cell. Reverse genetics utilizing a full-length infectious clone of the highly virulent CSFV strain Brescia (BICv) was used to evaluate how amino acid substitutions within this region of E2 may affect replication of BICv in cell cultures and affect virus virulence in swine. Interestingly, mutated virus FPi.c was completely attenuated when inoculated intranasally at a dose of 105 TCID50 in swine. Importantly, animals infected with FPi.c virus were protected against the virulent challenge with Brescia virus at 3 and 28 days after vaccination. Protection was evidenced by absence of clinical signs related with CSF as well as the absence of viremia produced by the challenge virulent virus.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: November 14, 2017
    Assignees: The United States of America, as represented by The Secretary of Agriculture, The University of Connecticut, Universidad del Pais Vasco/Euskal Herriko Univertsitatea (UPV-EHU)
    Inventors: Manuel V. Borca, Douglas P. Gladue, Lauren G. Holinka-Patterson, Vivian O'Donnell, Jose Nieva
  • Patent number: 9808520
    Abstract: African swine fever virus (ASFV) is the etiological agent of a contagious, often lethal viral disease of domestic pigs. The control of African Swine Fever (ASF) has been hampered by the unavailability of vaccines. Experimental vaccines have been derived from naturally occurring, cell culture-adapted, or genetically modified live attenuated ASFVs; however, these vaccines are only successful when protecting against homologous viruses. We have constructed a recombinant ?9GL/?UK virus derived from the highly virulent ASFV Georgia 2007 (ASFV-G) isolate by deleting the specific virulence-associated 9GL (B119L) and the UK (DP96R) genes. In vivo, ASFV-G ?9GL/?UK administered intramuscularly to swine even at relatively high doses (106 HAD50) does not induce disease. Importantly, animals infected with 104 or 106 HAD50 are solidly protected against the presentation of clinical disease when challenged at 28 days post infection with the virulent parental strain Georgia 2007.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: November 7, 2017
    Assignees: The United States of America as represented by The Secretary of Agriculture, The University of Connecticut
    Inventors: Manuel V. Borca, Douglas P. Gladue, Lauren G. Holinka-Patterson, Guillermo R. Risatti, Vivian K. O'Donnell
  • Publication number: 20170128563
    Abstract: The role of a specific E2 region, 869CKWGGNWTCV878, containing a putative fusion peptide (FP) sequence was evaluated. FPs critically contribute to the interaction between proteins and the membrane system of the host cell. Reverse genetics utilizing a full-length infectious clone of the highly virulent CSFV strain Brescia (BICv) was used to evaluate how amino acid substitutions within this region of E2 may affect replication of BICv in cell cultures and affect virus virulence in swine. A recombinant CSFV (FPi.c) containing mutations in three amino acid residues within the E2 protein area comprised CSFV amino acid residues 869-878 was constructed: W871T, W875D, and V878T. Interestingly, mutated virus FPi.c was completely attenuated when inoculated intranasally at a dose of 105 TCID50 in swine. Importantly, animals infected with FPi.c virus were protected against the virulent challenge with Brescia virus at 3 and 28 days after vaccination.
    Type: Application
    Filed: September 8, 2016
    Publication date: May 11, 2017
    Inventors: Manuel V. Borca, Douglas P. Gladue, Lauren G. Holinka-Patterson, Vivian O'Donnell, Jose Nieva